Study for Patients With Non Small Cell Lung Cancer (NSCLC)

Charité University Medicine Berlin

Status and phase: Unknown; Phase 2

Conditions: Carcinoma, Non-Small-Cell Lung

Treatments: Drug: Carboplatin; Drug: Vinorelbine; Drug: Paclitaxel

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT00168883

Haema CBF NSCLC UK/AS 03

Details and patient eligibility

About

This is a randomized study to assess the efficacy and safety of chemotherapy with platin compared to chemotherapy without platin.

Full description

Randomized Phase II design, multicenter study, to assess the efficacy and safety of combined chemotherapy with Paclitaxel and Carboplatin versus a platinum free chemotherapy with Paclitaxel and Vinorelbine, within the combination therapies there are two different dosing intervals, which will be assessed as well (4 Arm study).

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Chemotherapy naive patients with histologically confirmed NSCLC stage III and IV

Exclusion criteria

• New York Heart Association (NYHA) III or IV
• Brain metastases
• Neurotoxicity Grade 2 or greater

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)